LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis

Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, Atopic Dermatitis

Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

Published: 22 Oct, 2021 | Tags: Marinomed Biotech, Luoxin, Budesolv, budesonide nasal spray, Greater China

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

Published: 22 Oct, 2021 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, P-III PRIME2, Trial, Prurigo Nodularis

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Published: 22 Oct, 2021 | Tags: Scynexis, Ibrexafungerp, P-III, VANISH-303 Trial, Vaginal Yeast Infection

Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease

Published: 22 Oct, 2021 | Tags: Selecta, Genovis, IgG Protease, Gene Therapy, Autoimmune Disease

Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries

Published: 22 Oct, 2021 | Tags: Incyte, Specialised Therapeutics, Tafasitamab and Pemigatinib in Australia, New Zealand and Singapore

Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19

Published: 21 Oct, 2021 | Tags: Pfizer, BioNTech, COVID-19 Vaccine, Booster, P-III, Trial, COVID-19

Pfizer’s Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC's Advisory Committee Recommendation for Invasive Disease and Pneumonia

Published: 21 Oct, 2021 | Tags: Pfizer, Prevnar 20, Pneumococcal 20-Valent Conjugate Vaccine, CDC, Advisory Committee, Invasive Disease, Pneumonia

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for Antibody-Drug Conjugate Candidates

Published: 21 Oct, 2021 | Tags: Antengene, LegoChem Biosciences, Antibody-Drug Conjugate Candidates

Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma

Published: 21 Oct, 2021 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, US, FDA, Approval, Asthma

Sumitomo Dainippon Pharma Signs a Definitive Agreement with BehaVR to Develop and Commercialize PDTs and Wellness Product for CNS Disorders

Published: 21 Oct, 2021 | Tags: Sumitomo Dainippon Pharma, BehaVR, Prescription Digital Therapeutics, CNS Disorders

Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics

Published: 21 Oct, 2021 | Tags: Janssen, F-star, Multiple, Bispecific, Antibody Therapeutics

Dicerna Reports Results of Nedosiran in PHYOX4 Study for the Treatment of Primary Hyperoxaluria Type 3

Published: 20 Oct, 2021 | Tags: Dicerna, Nedosiran, PHYOX4 Study, Primary Hyperoxaluria Type 3

SpringWorks Enters into an Exclusive WW License Agreement with Academic Institutions to Advance Portfolio of Mutation-Selective EGFR Inhibitors

Published: 20 Oct, 2021 | Tags: SpringWorks, Academic Institutions, Portfolio, Mutation-Selective, EGFR Inhibitors

Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19

Published: 20 Oct, 2021 | Tags: Atea, AT-527, P-II, MOONSONG Trial, COVID-19

Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs

Published: 20 Oct, 2021 | Tags: Sana, Beam, CRISPR, Cas12b Nuclease System, Cell Therapy Programs

Antios Enters into a Clinical Collaboration Agreement with Assembly Biosciences to Evaluate ATI-2173 and Vebicorvir for Chronic Hepatitis B Virus Infection

Published: 20 Oct, 2021 | Tags: Antios, Assembly Biosciences, ATI-2173, Vebicorvir, Chronic Hepatitis B Virus Infection

Boehringer Ingelheim Exercised its Option to License Oxford Biomedica's Lentiviral Vector Technology to Commercialize BI 3720931 for CF

Published: 20 Oct, 2021 | Tags: Boehringer Ingelheim, License, Oxford Biomedica, Lentiviral Vector Technology, BI 3720931, CF

Lilly Published Results of Tirzepatide in SURPASS-4 Study for the Treatment of Type 2 Diabetes in The Lancet

Published: 19 Oct, 2021 | Tags: Lilly, Tirzepatide, SURPASS-4 Study, Type 2 Diabetes, The Lancet

Sanofi's Dupixent (dupilumab) Receives NICE Recommendation for the Treatment of Severe Asthma

Published: 19 Oct, 2021 | Tags: Sanofi, Dupixent, dupilumab, NICE, Severe Asthma

Takeda Signs an Agreement with Calithera to Acquire Sapanisertib and Mivavotinib

Published: 19 Oct, 2021 | Tags: Takeda, Calithera, Acquire, Sapanisertib, Mivavotinib

Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA's Approval for Expanded Indication to Treat HIV-1

Published: 19 Oct, 2021 | Tags: Gilead, Biktarvy, bictegravir, emtricitabine, tenofovir alafenamide, US, FDA, Approval, HIV-1

Takeda Amend its Collaboration with Wave Life Sciences to Advance CNS Programs

Published: 19 Oct, 2021 | Tags: Takeda, Wave Life Sciences, CNS Programs

Lipocine Enters into an Exclusive License Agreement with Antares to Commercialize Tlando in the US

Published: 19 Oct, 2021 | Tags: Lipocine, Antares, Tlando, US

Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer

Published: 18 Oct, 2021 | Tags: Innovent, Sintilimab, P-III, ORIENT-31 Study, EGFR-Mutated, Non squamous, Non-Small Cell Lung Cancer

Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program

Published: 18 Oct, 2021 | Tags: Ipsen, Accent, METTL3 program, AML

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar, ustekinumab in Russia and other CIS Countries

Published: 18 Oct, 2021 | Tags: Bio-Thera, Pharmapark, BAT2206, biosimilar, ustekinumab, Russia, CIS Countries

Boehringer Ingelheim's Cyltezo (biosimilar, adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases

Published: 18 Oct, 2021 | Tags: Boehringer Ingelheim, Cyltezo, biosimilar, adalimumab, US, FDA, sBLA, Approval, Inflammatory diseases

AbbVie' Skyrizi (risankizumab) Receives CHMP's Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the EU

Published: 18 Oct, 2021 | Tags: AbbVie, Skyrizi, Risankizumab, CHMP, Active Psoriatic Arthritis, EU

Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

Published: 18 Oct, 2021 | Tags: Genentech, Tecentriq, US, FDA, Approval, Non-Small Cell Lung Cancer

Related Post: PharmaShots Weekly Snapshots (October 11 - 15, 2021)